Boryeong Surpasses 400 Billion KRW in Sales for First Half of the Year... Steps Closer to 1 Trillion KRW Goal by 2026

Boryung's sales in the first half of the year exceeded 400 billion KRW for the first time in history. According to the provisional consolidated earnings announcement disclosed by Boryung on the 27th, Boryung's sales amounted to 420.1 billion KRW, a 16% increase compared to the same period last year. Operating profit rose 14% to 35 billion KRW compared to the same period last year.

Boryeong Headquarters Building Exterior
Photo by Boryeong

This represents Boryung's highest sales and operating profit for the first half of the year. A green light has also been turned on for achieving this year's target sales and operating profit of 810 billion KRW and 61 billion KRW, respectively. A Boryung official evaluated this as “the result of sustained high growth averaging 16% annually over the past three years.”

Sales in the prescription drug sector alone grew 20% to 348.8 billion KRW. Among these, the oncology segment surpassed 100 billion KRW in sales for the first time in the first half of the year, a 48% increase compared to the same period last year. This was the result of expanding the oncology portfolio with the full-scale sales of original drugs acquired through LBA such as 'Gemza' and 'Alimta', as well as biosimilars and oncology adjuvants. Respiratory treatments and antibiotics also made significant advances.

There was also strong performance from new drugs. Boryung's hypertension treatment product line, Kanarb, recorded sales of 69.5 billion KRW. Boryung aims to achieve Kanarb family sales of 200 billion KRW by 2026 through the 'Great Kanarb' strategy, which continuously introduces new combination drugs.

Plans are also in place to expand investment to nurture strategic products with competitiveness in multiple chronic disease areas such as diabetes and mental disorders. In the oncology business, Boryung intends to increase market share based on a diverse portfolio by cancer type, including LBA products and the newly introduced small cell lung cancer drug 'Zepzelca'.

Jang Doo-hyun, CEO of Boryung, stated, “We will focus our business capabilities to achieve the goal of 1 trillion KRW in sales by 2026 ahead of schedule,” and added, “We will do our best to ensure this leads to investment in future growth engines.”

This content was produced with the assistance of AI translation services.